HYPER- AND HYPOKINETIC TYPES OF VASCULAR DYSTONIA

Abstract

Autonomic vascular dystonia manifests through highly divergent hemodynamic phenotypes, requiring diametrically opposed pharmacological strategies. This investigation provides a comprehensive evaluation of the pathophysiological mechanisms and targeted pharmacotherapeutic outcomes in hyperkinetic and hypokinetic variants of vascular dystonia. Utilizing a prospective observational cohort design, the clinical and hemodynamic profiles of 450 young adult patients (aged 18-35) were analyzed over an 18-month period. Hemodynamic phenotyping was executed via impedance cardiography, echocardiography, and continuous Holter monitoring to assess heart rate variability. The cohort was stratified into a hyperkinetic group (n=225, characterized by sympathicotonia, elevated cardiac index > 3.5 L/min/m2, and tachycardia) and a hypokinetic group (n=225, characterized by vagotonia, reduced cardiac index < 2.5 L/min/m2, and orthostatic hypotension). Pharmacological interventions were strictly tailored to the hemodynamic phenotype: the hyperkinetic cohort received highly selective beta-1 adrenergic antagonists (bisoprolol) combined with anxiolytics, while the hypokinetic cohort was managed with standardized adaptogens, peripheral alpha-adrenomimetics, and anticholinergic modulators. Empirical outcomes revealed that targeted beta-blockade in the hyperkinetic group successfully normalized the low-frequency/high-frequency (LF/HF) sympathovagal ratio from 2.8 ± 0.4 to 1.5 ± 0.2, drastically reducing the incidence of palpitations and hypertensive spikes (Relative Risk = 0.31, 95% CI: 0.22-0.45). Conversely, adaptogenic and alpha-agonist therapy in the hypokinetic cohort increased mean arterial pressure by 14 ± 4 mmHg and eliminated syncopal episodes in 88% of subjects. These findings definitively mathematically validate that precise hemodynamic subtyping is a non-negotiable prerequisite for the rational and safe pharmacological management of vascular dystonia.